KRAS inhibitors

WO2025072457A1PCT designated stage expired Publication Date: 2025-04-03ELI LILLY & CO
View PDF 10 Cites 21 Cited by

Patent Information

Application Number
PCT/US2024/048575
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-27
Filing Date
2024-09-26
Publication Date
2025-04-03

Smart Images

  • Figure US2024048575_03042025_PF_FP_ABST
    Figure US2024048575_03042025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides compounds of the formula: wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compounds and uses thereof in the treatment of cancers and other medical conditions

    WO2017011920A1

  • KRAS g12c inhibitors

    WO2019099524A1

  • KRAS g12c inhibitors

    WO2020081282A1

  • KRAS g12c inhibitors

    WO2020101736A1

  • KRAS g12c inhibitors

    WO2020146613A1

Cited By

  • KRAS inhibitors

    US12600733B2

  • KRAS inhibitors

    US12691117B2

  • KRas inhibitors

    US12723053B2

  • KRAS inhibitor and pharmaceutical use thereof

    WO2025214344A1

  • Ras inhibitors

    WO2025240847A1